Andrew K. Burroughs

Hepatology · 2001–2016

A researcher in the Science corpus: 14 papers; trusts 2 researchers and is trusted by 3 researchers here, as inferred from the citation graph.

Subfields

• Hepatology — 93 citations into it; #58 of 151 by trust here, #25 by citations

Whom Andrew K. Burroughs trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. J. Llovet

Who trusts Andrew K. Burroughs overall

1. S. Friedman

Papers from Andrew K. Burroughs's perspective

Ordered by how strongly the researchers Andrew K. Burroughs trusts endorse each paper. Same corpus, a different order for every researcher.

1. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations (British medical journal)
2. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis (Gut)
3. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. (The Lancet)
4. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival (Hepatology)
5. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. (Gastroenterology)
6. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma (Hepatology)
7. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. (The Lancet)
8. The Survival Benefit of Liver Transplantation (American Journal of Transplantation)
9. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. (Gastroenterology)
10. A unification of models for meta-analysis of diagnostic accuracy studies. (Biostatistics)

Their papers

• EASL Clinical Practice Guidelines: Liver transplantation. (2016) — 760 citations
• Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. (2014) — 865 citations
• Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions (2012) — 653 citations
• A Systematic Review of Microvascular Invasion in Hepatocellular Carcinoma: Diagnostic and Prognostic Variability (2012) — 613 citations
• Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). (2012) — 853 citations
• Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. (2011) — 742 citations
• Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. (2010) — 1,152 citations
• Computer‐assisted image analysis of liver collagen: Relationship to Ishak scoring and hepatic venous pressure gradient (2009) — 302 citations
• Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. (2009) — 1,897 citations
• Transarterial Therapy for Hepatocellular Carcinoma: Which Technique Is More Effective? A Systematic Review of Cohort and Randomized Studies (2007) — 848 citations
• Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. (2007) — 1,085 citations
• Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. (2005) — 963 citations
• Hepatocellular carcinoma (2003) — 717 citations
• Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. (2001) — 4,137 citations